Session Synopsis: Cancer genomics can improve outcomes and reduce costs. The challenge clinical laboratories face is how to choose from a complex set of unequal partial solutions for biochemistry, bioinformatics and clinical interpretation while meeting the regulatory requirements and providing cost effective services. We propose a simple end-to-end complete solution from tumor to clinical action.
Session Chair Profile
Ph.D., President and Chief Executive Officer, Toma Biosciences
Wolfgang is an executive and serial entrepreneur in healthcare (diagnostics, medical devices, and health services). Currently he serves as Chairman and CEO of TOMA Biosciences, Inc., a fast growing genomic cancer diagnostic company. Previously Wolfgang was President/CEO of companies Knome (genome interpretation), Castlewood Surgical (heart bypass surgery), Boston Heart Lab (heart diagnostic / Lipidology, and now under Bain one of the fastest growing diagnostic companies in the US), BrainVital (epilepsy), Thermonix (in-stent restenosis), CardioTools (angiography), and Daum (MRI); and relocated with a company acquisition from Germany to the US in 2001. Wolfgang holds a M.S. in Physics from University of Göttingen and a PhD from Technical University Hamburg-Harburg, both Germany. He is a Board member of medical company Precisis and an active angel investor with Launchpad Angels in Boston.
D.Sc., Department of Genetics, Stanford University School of Medicine
Dr. De La Vega is an accomplished Genomics and Computational Biology Scientist. He spent 13 years at Applied Biosystems (currently Life Technologies), where he was the Distinguished Scientific Fellow, Vice President of Next-Generation Sequencing Applications, and a distinguished inventor, founding member of the Life Technologies’ i2 (Invention x Innovation) Society. He is currently a Visiting Instructor at the Department of Genetics of the Stanford University School of Medicine where he studies the structure of human populations through whole-genome sequencing, how to interpret this variation for clinical purposes and coordinates a research project where knowledgeable genetics professionals are being sequenced to obtain a medical interpretation of their genomes. Francisco earned his Doctor of Science degree in Genetics and Molecular Biology at CINVESTAV (Mexico), studying the genetic regulation of protein biosynthesis in the bacteria/bacteriophage system with emphasis in the computational analysis.
M.D., Medical Oncologist and Director of Medical Oncology, Intermountain Healthcare
Derrick Haslem, MD, is a Medical Oncologist and Director of Medical Oncology for Intermountain Healthcare. Dr. Haslem is a board-certified specialist in internal medicine and medical oncology with expertise in targeted therapy. Dr. Haslem received his medical degree from the University of Utah School of Medicine and Residency and Fellowship training at the University of Utah Medical Center. Dr. Haslem has Board Certifications in Internal Medicine and Medical Oncology. He lives in St. George, Utah, with his wife and their five children.
Ph.D., CEO, DiagCor
Dr. Joseph W. O. Tam, Ph.D., serves as Chairman and Chief Executive Officer at DiagCor Bioscience Incorporation Limited. Dr. Tam is a research pioneer with over 30 years of teaching and research experience in the biotechnology and diagnostics sector. He is the Founder and President of the Hong Kong Biochemistry Association. Dr. Tam is a Visiting Professor at UCSF, Baylor Medical College and Medical College of Georgia, Scientist of National Institute of Health, Associate Professor and Honorary Associate Professor of Medical Faculty of Hong Kong University.